
July 25 (Reuters) - EMA:
EMA: ON 18 JULY, NORGINE B.V. WITHDREW APPLICATION FOR MARKETING AUTHORISATION OF IFINWIL FOR TREATMENT OF HIGH-RISK NEUROBLASTOMA
EMA: IN APPLICATION WITHDRAWAL LETTER, NORGINE SAID IT NEEDED ADDITIONAL TIME TO COMPREHENSIVELY ADDRESS ALL QUESTIONS RAISED BY EMA ABOUT IFINWIL